Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSIC: Nirsevimab in Immunocompromised Children
NCT04484935Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by AstraZeneca. Started Aug 2020; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04484935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484935.